BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33967153)

  • 1. [Predisposition and progression of myelodysplastic syndromes].
    Makishima H
    Rinsho Ketsueki; 2021; 62(4):278-288. PubMed ID: 33967153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of clonal evolution in myelodysplastic syndromes.
    Makishima H; Yoshizato T; Yoshida K; Sekeres MA; Radivoyevitch T; Suzuki H; Przychodzen B; Nagata Y; Meggendorfer M; Sanada M; Okuno Y; Hirsch C; Kuzmanovic T; Sato Y; Sato-Otsubo A; LaFramboise T; Hosono N; Shiraishi Y; Chiba K; Haferlach C; Kern W; Tanaka H; Shiozawa Y; Gómez-Seguí I; Husseinzadeh HD; Thota S; Guinta KM; Dienes B; Nakamaki T; Miyawaki S; Saunthararajah Y; Chiba S; Miyano S; Shih LY; Haferlach T; Ogawa S; Maciejewski JP
    Nat Genet; 2017 Feb; 49(2):204-212. PubMed ID: 27992414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.
    West RR; Calvo KR; Embree LJ; Wang W; Tuschong LM; Bauer TR; Tillo D; Lack J; Droll S; Hsu AP; Holland SM; Hickstein DD
    Blood Adv; 2022 Feb; 6(3):793-807. PubMed ID: 34529785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and significance of DDX41 gene variants in the general population.
    Cheloor Kovilakam S; Gu M; Dunn WG; Marando L; Barcena C; Nik-Zainal S; Mohorianu I; Kar SP; Fabre MA; Quiros PM; Vassiliou GS
    Blood; 2023 Oct; 142(14):1185-1192. PubMed ID: 37506341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Karantanos T; Gondek LP; Varadhan R; Moliterno AR; DeZern AE; Jones RJ; Jain T
    Br J Haematol; 2021 Jun; 193(6):1142-1150. PubMed ID: 34028801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders.
    Trottier AM; Feurstein S; Godley LA
    Best Pract Res Clin Haematol; 2024 Mar; 37(1):101537. PubMed ID: 38490765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
    Makishima H; Saiki R; Nannya Y; Korotev S; Gurnari C; Takeda J; Momozawa Y; Best S; Krishnamurthy P; Yoshizato T; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Nagata Y; Kakiuchi N; Onizuka M; Chiba K; Tanaka H; Kon A; Ochi Y; Nakagawa MM; Okuda R; Mori T; Yoda A; Itonaga H; Miyazaki Y; Sanada M; Ishikawa T; Chiba S; Tsurumi H; Kasahara S; Müller-Tidow C; Takaori-Kondo A; Ohyashiki K; Kiguchi T; Matsuda F; Jansen JH; Polprasert C; Blombery P; Kamatani Y; Miyano S; Malcovati L; Haferlach T; Kubo M; Cazzola M; Kulasekararaj AG; Godley LA; Maciejewski JP; Ogawa S
    Blood; 2023 Feb; 141(5):534-549. PubMed ID: 36322930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Of gains and losses: SAMD9/SAMD9L and monosomy 7 in myelodysplastic syndrome.
    Cammenga J
    Exp Hematol; 2024 Jun; 134():104217. PubMed ID: 38649131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.
    Schratz KE; DeZern AE
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):333-356. PubMed ID: 32089214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope.
    Elghetany MT; Patnaik MM; Khoury JD
    Leuk Res; 2024 Feb; 137():107441. PubMed ID: 38301422
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Yin CC; Tam W; Walker SM; Kaur A; Ouseph MM; Xie W; K Weinberg O; Li P; Zuo Z; Routbort MJ; Chen S; Medeiros LJ; George TI; Orazi A; Arber DA; Bagg A; Hasserjian RP; Wang SA
    Haematologica; 2024 Jun; 109(6):1825-1835. PubMed ID: 37981812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression.
    Montes P; Bernal M; Campo LN; González-Ramírez AR; Jiménez P; Garrido P; Jurado M; Garrido F; Ruiz-Cabello F; Hernández F
    Cancer Immunol Immunother; 2019 Dec; 68(12):2015-2027. PubMed ID: 31705171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy.
    Lao Z; Ding LW; Sun QY; Jia L; Yan B; Ng AY; Capinpin SM; Wang R; Ying L; Chng WJ; Koeffler HP; Koh WP; Yuan JM; Yang H; Goh YT; Grigoropoulos N
    Clin Cancer Res; 2024 May; 30(10):2170-2180. PubMed ID: 38437679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy.
    Yu K; Deuitch N; Merguerian M; Cunningham L; Davis J; Bresciani E; Diemer J; Andrews E; Young A; Donovan F; Sood R; Craft K; Chong S; Chandrasekharappa S; Mullikin J; Liu PP
    Blood Adv; 2024 Jan; 8(2):497-511. PubMed ID: 38019014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
    Abdulbaki R; Pullarkat ST
    Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies.
    Brune MM; Rau A; Overkamp M; Flaadt T; Bonzheim I; Schürch CM; Federmann B; Dirnhofer S; Fend F; Tzankov A
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia.
    Liu L; Zhang D; Fu Q; Wang J; Yu J; Chen D; Wang F; Guo R; Xie X; Jiang Z; Li Y
    Clin Exp Med; 2023 Dec; 23(8):4473-4482. PubMed ID: 37087521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How I diagnose myeloid neoplasms with germline predisposition.
    Patel N; Calvo KR
    Am J Clin Pathol; 2023 Oct; 160(4):352-364. PubMed ID: 37458302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.
    Cargo C; Bernard E; Beinortas T; Bolton KL; Glover P; Warren H; Payne D; Ali R; Khan A; Short M; Van Hoppe S; Smith A; Taylor J; Evans P; Papaemmanuil E; Crouch S
    Lancet Haematol; 2024 Jan; 11(1):e51-e61. PubMed ID: 38135373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Banaszak LG; Cabral PL; Smith-Simmer K; Hassan A; Brunner M; Fallon M; Shoger K; Lovrien L; Golner D; Zurbriggen L; Mattison R; Gahvari Z; Hall A; Nadiminti K; Reinig E; Churpek JE
    JCO Precis Oncol; 2024 Jun; 8():e2300518. PubMed ID: 38848520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.